An Open-label, Dose-escalation, Safety and Pharmacokinetics Phase I Study of Ombrabulin in Combination With Paclitaxel and Carboplatin Every 3 Weeks in Patients With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 03 Nov 2015
At a glance
- Drugs Carboplatin (Primary) ; Ombrabulin (Primary) ; Paclitaxel (Primary)
- Indications Carcinoma; Lung cancer; Ovarian cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Sanofi
- 01 Nov 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 05 Sep 2013 Planned end date changed from 1 Sep 2013 to 1 Nov 2013 as reported by ClinicalTrials.gov.
- 10 Jun 2013 Planned End Date changed from 1 Jun 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.